By Blake N. Shultz and Gregory Curfman
Despite a troubling history, rofecoxib (Vioxx) may be making a comeback.
The voluntary withdrawal of rofecoxib (Vioxx) from the market in September 2004 marked the end of a controversial era for a once highly profitable and widely used drug. It also marked the beginning of years of high-profile product-liability litigation that would cost Merck billions.